• Axogen Q2 revenue rose 23.1% to USD 69.7 million from a year earlier.
• Net results swung to a loss of USD 1.5 million, or USD 0.03 per share.
• Gross margin fell 1.5 percentage points to 72.7%, driven by product-mix changes tied to breast growth above 50%.
• Adjusted EBITDA slipped to USD 8.4 million from a year earlier.
• Raised 2026 revenue outlook to at least USD 279 million, implying at least 24% growth; expects gross margin at least 73%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.